Corporate Finance

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

With $70M and a new CEO, Prolynx is leveraging a cancer-tested platform to create monthly obesity shots. Can it disrupt a billion-dollar market?

As national banks celebrate rising satisfaction from digital innovation, a new study reveals a silent crisis: older customers are being left behind.

Apollo Silver plans to revive a massive California silver deposit, aligning with US strategic goals. Can it overcome technical and environmental hurdles?

Sarepta Therapeutics is trading higher interest costs for a longer financial runway. We decode the biotech's complex debt deal and what it signals.

Canadian grocer Empire posts strong sales but lower earnings. A deep dive into its dual strategy of store renewal and a major digital and data overhaul.

Dreame's 2025 holiday sale isn't just about vacuums; it's a strategic play to conquer the UK market with premium tech at aggressive prices.

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.

Salesforce's AI agents are set to overhaul the USDOT, tackling legacy tech to speed up grants, enhance safety, and redefine federal efficiency.

Target's holiday push is more than a sale; it's a high-stakes play using AI, exclusive drops, and logistics to win the final days of retail's biggest battle.

As Cook County faces its 31st straight year of property tax hikes, a new digital tool aims to help struggling homeowners avoid a looming financial cliff.

Fidelity and TIAA still lead, but strategic AI investments are fueling a surge from mid-tier players, redefining the competitive retirement landscape.

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

With a massive $550M capital infusion, Immunovant is poised to accelerate its novel Graves' Disease therapy, IMVT-1402, toward commercial launch.

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

A new 8MWh energy storage system in Matsusaka showcases how advanced technology is helping Japan balance industrial power with its green energy ambitions.

With rare dual Google accreditations, Audiencerate offers a blueprint for privacy-first advertising in a world without third-party cookies.

A new partnership aims to bypass slow, costly banking rails, using stablecoins to unlock faster, cheaper global transactions for businesses. Is this the future?

SSC's 37th dividend payment signals stability, but high payout ratios raise questions. Is management's growth-and-buyback strategy the right bet?